Meta Platforms
META
MARA Holdings
MARA
Toll Brothers
TOL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
US Stock MarketDetailed Quotes
TGTX TG Therapeutics
- 42.360
- -0.110-0.26%
Trading Mar 20 11:51 ET
6.65BMarket Cap282.40P/E (TTM)
43.030High41.640Low641.18KVolume42.280Open42.470Pre Close27.16MTurnover0.44%Turnover Ratio282.40P/E (Static)157.07MShares43.03052wk High29.92P/B6.20BFloat Cap12.93052wk Low--Dividend TTM146.32MShs Float149414.006Historical High--Div YieldTTM3.27%Amplitude0.956Historical Low42.361Avg Price1Lot Size
TG Therapeutics News
TG Therapeutics: Strategic Positioning and Growth Potential Drive Buy Rating
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $53
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $10 to $55
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), BioLife Solutions (BLFS) and Surgery Partners (SGRY)
TG Therapeutics Analyst Ratings
Strong Financial Performance and Promising Outlook Drive Buy Rating for TG Therapeutics
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
Bank of America Securities Sticks to Its Sell Rating for TG Therapeutics (TGTX)
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
TG Therapeutics Analyst Ratings
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $38
B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $10
BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)
TG Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.